Alex Manini, MD
img_Alex Manini
PROFESSOR | Emergency Medicine
Are you a patient?
Emergency Medicine
Adverse Cardiovascular Events from Drug Overdose

In 2015, Dr. Manini received the Empire Clinical Research Investigator Program (ECRIP) from the New York, State Department of Health entitled Simulation Outcomes Research for ACLS.  He also received Promotion of Diversity in Health Related Research from the National Institute on Drug Abuse entitled, Opiate co-ingestion as a risk factor for acetaminophen hepatotoxicity.  Additionally, Dr. Manini received from the  NIH an Administrative Supplement from the National Institute on Drug Abuse (NIH/NIDA) entitled Assessment of novel serum biomarkers.

In 2014, Dr. Manini received a five-year Research Project Grant (R01) from the National Institute on Drug Abuse at the NIH. The award involves collaboration between Mount Sinai investigators in neuroscience, cardiology, epidemiology, emergency medicine, and medical toxicology, along with co-investigators from the NYU School of Medicine and the Toxicology Investigators’ Consortium, a national registry sponsored by the American College of Medical Toxicology. Clinical studies launched by the R01 will test a broad array of risk prediction instruments, laboratory biomarkers, and opioid receptor gene polymorphisms, with the goal to produce clinical tools to individualize prevention strategies for curtailing the national rise in drug overdose fatality.

In 2014, Dr. Manini was appointed Site PI of the NIDA National Early Warning System Network (iN3). The study is funded by an NIH High Priority Short Term Project (R56) from the National Institute on Drug Abuse. The goal of the study is to identify new episodes of emerging drug use nationally to advance drug surveillance from a reactive to anticipatory science.

In 2009, Dr. Manini received a Career Development Grant Award (K23) from the National Institute on Drug Abuse at the NIH. Mentored by David Vlahov, PhD and Lynne Richardson, MD, Dr. Manini studied clinical risk factors for adverse cardiovascular events in drug overdose emergencies.





BS, Massachusetts Institute of Technology

MD, University of California San Francisco

Brigham & Women's Hospital / Massachusetts General Hospital Harvard Medical School

Brigham & Women's Hospital / Massachusetts General Hospital Harvard Medical School

MS, New York University

Bellevue Hospital Center - NYU School of Medicine

MD, UCSF School of Medicine

Residency, Emergency Medicine, Brigham & Womens Hospital

Fellowship, Emergency Medicine, Medical Toxicology, NYU Grossman School of Medicine


American Board of Emergency Medicine


NIH Study Section Member, CEBRA (Cutting Edge Basic Research Awards)


Top Consultant, Annals of Emergency Medicine


Young Investigator Award WINNER, XXXIII International Congress



Senior Reviewer

Annals of Emergency Medicine


Fellow of the American College of Medical Toxicology



NIH Early Career Reviewer (ECR), Center for Scientiic Review


The Dr. Harold and Golden Lamport Reseach Award

Mount Sinai School of Medicine


Young Investigator of the Year

Society of Academic Emergency Medicine (SAEM)

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Manini has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.